Published in J Clin Oncol on May 10, 2010
Factors affecting uptake and adherence to breast cancer chemoprevention: a systematic review and meta-analysis. Ann Oncol (2015) 2.17
Use of tamoxifen and raloxifene for breast cancer chemoprevention in 2010. Breast Cancer Res Treat (2012) 1.66
Future directions in cancer prevention. Nat Rev Cancer (2012) 1.62
Risk-benefit profiles of women using tamoxifen for chemoprevention. J Natl Cancer Inst (2014) 1.51
Long-term outcomes of BRCA1/BRCA2 testing: risk reduction and surveillance. Cancer (2011) 1.41
Selective estrogen receptor modulators and pharmacogenomic variation in ZNF423 regulation of BRCA1 expression: individualized breast cancer prevention. Cancer Discov (2013) 1.12
Uptake of tamoxifen in consecutive premenopausal women under surveillance in a high-risk breast cancer clinic. Br J Cancer (2014) 1.01
Major clinical research advances in gynecologic cancer in 2011. J Gynecol Oncol (2012) 0.97
Decision aids for breast cancer chemoprevention. Breast Cancer Res (2013) 0.96
Acceptance and adherence to chemoprevention among women at increased risk of breast cancer. Breast (2014) 0.90
Exemestane for breast cancer prevention: a critical shift? Cancer Discov (2012) 0.85
Barriers and Facilitators to Patient-Provider Communication When Discussing Breast Cancer Risk to Aid in the Development of Decision Support Tools. AMIA Annu Symp Proc (2015) 0.85
Pharmacogenomics of endocrine therapy in breast cancer. J Hum Genet (2013) 0.84
Chemoprevention for Breast Cancer. Ann Surg Oncol (2015) 0.83
CYP2D6 genotyping and tamoxifen: an unfinished story in the quest for personalized medicine. Semin Oncol (2011) 0.83
Tamoxifen vs Raloxifene vs Exemestane for Chemoprevention. Curr Breast Cancer Rep (2012) 0.82
Uptake of a randomized breast cancer prevention trial comparing letrozole to placebo in BRCA1/2 mutations carriers: the LIBER trial. Fam Cancer (2012) 0.82
What Matters to Women When Making Decisions About Breast Cancer Chemoprevention? Patient (2016) 0.81
Tamoxifen Initiation After Ductal Carcinoma In Situ. Oncologist (2016) 0.81
Lobular Carcinoma in Situ: A 29-Year Longitudinal Experience Evaluating Clinicopathologic Features and Breast Cancer Risk. J Clin Oncol (2015) 0.81
Breast Cancer Chemoprevention among High-risk Women and those with Ductal Carcinoma In Situ. Breast J (2015) 0.81
My Lived Experiences Are More Important Than Your Probabilities: The Role of Individualized Risk Estimates for Decision Making about Participation in the Study of Tamoxifen and Raloxifene (STAR). Med Decis Making (2015) 0.80
Affective forecasting and medication decision making in breast-cancer prevention. Health Psychol (2016) 0.79
Exemestane in the prevention setting. Ther Adv Med Oncol (2012) 0.79
Barriers to preventive therapy for breast and other major cancers and strategies to improve uptake. Ecancermedicalscience (2015) 0.77
Uptake of exemestane chemoprevention in postmenopausal women at increased risk for breast cancer. Eur J Cancer Prev (2016) 0.75
Establishing a program for individuals at high risk for breast cancer. J Cancer (2013) 0.75
Cancer Prevention: Lessons Learned and Future Directions. Trends Cancer (2016) 0.75
Usability Testing of a Web-Based Decision Aid for Breast Cancer Risk Assessment Among Multi-Ethnic Women. AMIA Annu Symp Proc (2017) 0.75
Clinical Trial of Acolbifene in Premenopausal Women at High Risk for Breast Cancer. Cancer Prev Res (Phila) (2015) 0.75
Physician and Patient Barriers to Breast Cancer Preventive Therapy. Curr Breast Cancer Rep (2016) 0.75
Combination of Antiestrogens and Omega-3 Fatty Acids for Breast Cancer Prevention. Biomed Res Int (2015) 0.75
Impact of self-reported data on the acquisition of multi-generational family history and lifestyle factors among women seen in a high-risk breast screening program: a focus on modifiable risk factors and genetic referral. Breast Cancer Res Treat (2017) 0.75
Decision making for breast cancer prevention among women at elevated risk. Breast Cancer Res (2017) 0.75
Motivators and barriers of tamoxifen use as risk-reducing medication amongst women at increased breast cancer risk: a systematic literature review. Hered Cancer Clin Pract (2017) 0.75
Introducing a Comprehensive Informatics Framework to Promote Breast Cancer Risk Assessment and Chemoprevention in the Primary Care Setting. AMIA Jt Summits Transl Sci Proc (2017) 0.75
How do we increase uptake of tamoxifen and other anti-estrogens for breast cancer prevention? NPJ Breast Cancer (2017) 0.75
Chemoprevention Uptake among Women with Atypical Hyperplasia and Lobular and Ductal Carcinoma In Situ. Cancer Prev Res (Phila) (2017) 0.75
Chemoprevention of Breast Cancer by Transdermal Delivery of α-Santalol through Breast Skin and Mammary Papilla (Nipple). Pharm Res (2017) 0.75
Deciding on breast cancer risk reduction: The role of counseling in individual decision-making - A qualitative study. Patient Educ Couns (2017) 0.75
Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA (2000) 55.37
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med (2009) 35.37
Unwarranted variations in healthcare delivery: implications for academic medical centres. BMJ (2002) 4.63
Modifying unwarranted variations in health care: shared decision making using patient decision aids. Health Aff (Millwood) (2004) 4.19
Promoting informed decisions about cancer screening in communities and healthcare systems. Am J Prev Med (2004) 3.93
Risk communication in practice: the contribution of decision aids. BMJ (2003) 3.55
American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. J Clin Oncol (2009) 3.51
Estimates of the number of US women who could benefit from tamoxifen for breast cancer chemoprevention. J Natl Cancer Inst (2003) 2.48
Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. QUOROM Group. Br J Surg (2000) 2.40
Patient reluctance toward tamoxifen use for breast cancer primary prevention. Ann Surg Oncol (2001) 1.94
Making good decisions about breast cancer chemoprevention. Ann Intern Med (2002) 1.67
Uptake rates for breast cancer genetic testing: a systematic review. Cancer Epidemiol Biomarkers Prev (2006) 1.58
Assessing hypothetical scenario methodology in genetic susceptibility testing analog studies: a quantitative review. Genet Med (2007) 1.52
American Society of Clinical Oncology technology assessment on breast cancer risk reduction strategies: tamoxifen and raloxifene. J Clin Oncol (1999) 1.52
Women's decisions regarding tamoxifen for breast cancer prevention: responses to a tailored decision aid. Breast Cancer Res Treat (2010) 1.47
Decision-making about tamoxifen in women at high risk for breast cancer: clinical and psychological factors. J Clin Oncol (2004) 1.46
Preferences of Women Evaluating Risks of Tamoxifen (POWER) study of preferences for tamoxifen for breast cancer risk reduction. Cancer (2005) 1.43
Breast cancer risk reduction options: awareness, discussion, and use among women from four ethnic groups. Cancer Epidemiol Biomarkers Prev (2006) 1.39
Tamoxifen for breast cancer chemoprevention: low uptake by high-risk women after evaluation of a breast lump. Ann Fam Med (2005) 1.28
"Why take it if you don't have anything?" breast cancer risk perceptions and prevention choices at a public hospital. J Gen Intern Med (2006) 1.21
Women's views on chemoprevention of breast cancer: qualitative study. Can Fam Physician (2006) 1.21
The dilemma and promise of cancer chemoprevention. Nat Clin Pract Oncol (2006) 1.18
Prescription of tamoxifen for breast cancer prevention by primary care physicians. Arch Intern Med (2006) 1.12
Women's interest in chemoprevention for breast cancer. Arch Intern Med (2001) 1.10
Attitudes to prophylactic surgery and chemoprevention in Australian women at increased risk for breast cancer. J Womens Health (Larchmt) (2003) 1.05
"I'm going to die of something anyway": women's perceptions of tamoxifen for breast cancer risk reduction. Ethn Dis (2005) 1.04
Assessment of genetic testing and related counseling services: current research and future directions. Soc Sci Med (2004) 1.01
Chemoprevention of breast cancer with selective estrogen receptor modulators: views from broadly diverse focus groups of women with elevated risk for breast cancer. Psychooncology (2001) 0.99
Aversion to side effects in preventive medical treatment decisions. Br J Health Psychol (2007) 0.96
Atypia in random periareolar fine-needle aspiration affects the decision of women at high risk to take tamoxifen for breast cancer chemoprevention. Cancer Epidemiol Biomarkers Prev (2007) 0.92
How should we inform women at higher risk of breast cancer about tamoxifen? An approach with a decision guide. Breast Cancer Res Treat (2005) 0.91
Standard consultations are not enough to ensure decision quality regarding preference-sensitive options. J Natl Cancer Inst (2003) 0.91
Proportional odds ratio model for comparison of diagnostic tests in meta-analysis. BMC Med Res Methodol (2004) 0.89
The impact of breast cancer awareness and socioeconomic status on willingness to receive breast cancer prevention drugs. Breast Cancer Res Treat (2006) 0.88
Interest in breast cancer chemoprevention among older women. Breast Cancer Res Treat (2007) 0.88
The estimation and use of absolute risk for weighing the risks and benefits of selective estrogen receptor modulators for preventing breast cancer. Ann N Y Acad Sci (2001) 0.87
Repeated-measures modeling improved comparison of diagnostic tests in meta-analysis of dependent studies. J Clin Epidemiol (2004) 0.86
Breast cancer chemoprevention - a vision not yet realized. Eur J Cancer Care (Engl) (2009) 0.84
Acceptance of tamoxifen chemoprevention by physicians and women at risk. Cancer (2005) 0.80
Tamoxifen for breast cancer risk reduction: impact of alternative approaches to quality-of-life adjustment on cost-effectiveness analysis. Med Care (2008) 0.79
D-dimer testing for deep venous thrombosis: a metaanalysis. Clin Chem (2004) 1.83
Uptake rates for breast cancer genetic testing: a systematic review. Cancer Epidemiol Biomarkers Prev (2006) 1.58
Free clinics: a national survey. Am J Med Sci (2005) 0.87
Prophylactic vena cava filters for trauma patients: a systematic review of the literature. Thromb Res (2003) 0.86
Repeated-measures modeling improved comparison of diagnostic tests in meta-analysis of dependent studies. J Clin Epidemiol (2004) 0.86
Free clinics and the uninsured: the increasing demands of chronic illness. J Health Care Poor Underserved (2003) 0.81
D-dimer and venous thromboembolism. Ann Intern Med (2004) 0.77
Amiodarone versus lidocaine for shock-resistant ventricular fibrillation. N Engl J Med (2002) 0.75